Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 86

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 86
---
 of grant.(2)The expected dividend yield is zero as the Company has not paid any dividends to date and does not expect to pay dividends in the future.(3)The expected term is estimated using historical exercise behavior. (4)The expected volatility is the implied volatility in exchange-traded options of the Company’s common stock. The amounts estimated according to the Black-Scholes-Merton option-pricing model may not be indicative of the actual values realized upon the exercise of these options by the holders.

F-30

The following table summarizes the Company’s stock option activity for the period indicated: 

        For the Year Ended December 31, 2024

        Weighted-Average

        Shares

        Exercise Price

        Grants outstanding at beginning of the period

        9,582,695

        $
        78.57

        Granted

        331,920

        128.89

        Exercised

        (850,117
        )

        79.33

        Cancelled and forfeited

        (180,026
        )

        122.38

        Grants outstanding at end of the period

        8,884,472

        $
        79.49

        Grants exercisable at end of the period

        6,267,957

        $
        77.66

        Grants vested and expected to vest at end of the period

        8,726,976

        $
        78.66

      The weighted-average grant date fair value per share of stock options granted during the years ended December 31, 2024, 2023 and 2022 was $67.31, $70.94 and $48.82, respectively.  

        Weighted-Average

        Aggregate

        Remaining

        Intrinsic Value

        Contractual

        (in thousands)

        Life (Years)

        Options outstanding at December 31, 2024
         
        $
        425,039

        4.8

        Options exercisable at December 31, 2024
         
        $
        307,232

        4.4

        Options vested and expected to vest at December 31, 2024
         
        $
        423,367

        4.7

       The following table summarizes the Company’s shares vested and stock options exercised for each of the periods indicated: 

        For the Year Ended December